In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans | Zendy

N X Chin | Zendy; Irene Weitzman | Zendy; Phyllis DellaLatta | Zendy

Open Access

In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans

Author(s) -

N X Chin,

Irene Weitzman,

Phyllis DellaLatta

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.4.850

Subject(s) - itraconazole , cryptococcus neoformans , fluvastatin , fluconazole , microbiology and biotechnology , cryptococcus , minimum inhibitory concentration , cryptococcosis , pharmacology , in vitro , biology , cholesterol , chemistry , antifungal , biochemistry , antibiotics , simvastatin

Fluvastatin, a cholesterol-lowering drug, exhibited minimal activity (MICs of 64 to >128 microg/ml) against Candida species and Cryptococcus neoformans. When fluvastatin was combined with fluconazole or itraconazole, both synergistic and additive effects were noted (fractional inhibitory concentration indices of < or = 0.156 to 0.625; fractional lethal concentration indices of < or = 0.156 to 0.75). This combined fungicidal activity was confirmed by time-versus-killing studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research